P213 - ASSOCIATIONS BETWEEN CIRCULATING FGF21 LEVELS, BODY COMPOSITION, AND FUNCTIONAL PERFORMANCE IN PATIENTS WITH OBESITY AFTER ONE YEAR OF TREATMENT

P213

ASSOCIATIONS BETWEEN CIRCULATING FGF21 LEVELS, BODY COMPOSITION, AND FUNCTIONAL PERFORMANCE IN PATIENTS WITH OBESITY AFTER ONE YEAR OF TREATMENT

D. G. Ariadel-Cobo¹, B. Estébanez-González², E. González-Arnáiz¹, M. J. Cuevas-González², P. García-Pérez¹, D. García-Sastre¹, M. BALLESTEROS-POMAR^1,*

¹Endocrinología y Nutrición, Complejo Asistencial Universitario de León , ²Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain

Rationale: Fibroblast Growth Factor 21 (FGF21) is a key regulator of metabolic homeostasis, insulin sensitivity, and energy balance, with levels shown to increase following weight loss and metabolic interventions. 

Methods: A cross-sectional study was conducted in 26 patients with obesity after one year of treatment, assessing body composition via BIA and functional performance through handgrip strength, chair stand, and speed lifted tests. Pearson correlation and multiple linear regression analyses were performed to explore associations between FGF21 levels and metabolic or functional variables.

Results: 26 patients (69.2% women, 30.8% men, mean age: 54 years). The weight was 105.5 kg (19.3) and BMI 38.6 kg/m² (7.4). The fat mass (FM) was 41.9 kg (4.4), lean mass 60.2 kg (9.2), and waist circumference 116.7 cm (15.9). Regarding muscle strength and functional performance, the handgrip strength was 29.3 kg (SD 10.6), chair stand test 15.5 repetitions (7.4), speed lifted test 6.7 s (2.0), and stability test 45.8 points (10.1).

FGF21 showed no significant correlations with body composition or functional performance, though a negative trend with relative FM (r= -0.247, p = 0.234) was observed. The regression model (R² = 0.553, p = 0.209) suggested a potential inverse association with MG/Weight, B = -43.26, p = 0.073), but no other predictors reached significance.

Conclusion: In this cohort of patients with obesity after one year of treatment, FGF21 levels were not significantly associated with body composition or functional performance, although a trend toward lower levels with higher fat mass was noted. These findings, along with previous evidence of FGF21 increases following metabolic interventions, suggest a potential adaptive role that warrants further investigation in larger samples.

References: Prida, E et al. Liver Brain Interactions:. Int. J. Mol. Sci. 2022, 23, 13318.

Disclosure of Interest: None declared